news aktuell GmbH

Press release of the German Publishers and Booksellers Association

Share

Ewald Frie receives the German Non-Fiction Prize 2023 for his work “Ein Hof und elf Geschwister”

The winner of the German Non-Fiction Prize 2023 is Ewald Frie for his book “Ein Hof und elf Geschwister. Der stille Abschied vom bäuerlichen Leben in Deutschland” (“A Farm and Eleven Siblings. The Quiet Farewell to Rural Life in Germany”) (Publishers C.H.Beck).

Statement from the jury:

“People everywhere are quietly bidding farewell to rural life. Ewald Frie takes a surprising and personal perspective on this process of change. Using his family from the Münsterland region as an example, he describes tensions that have developed between town and country, and which we are currently grappling with intensely. With his astonishingly simple yet also poetic language – always empathetic, never nostalgic – Frie allows us to enter a world in transition. Based on interviews with his siblings, Ewald Frie has written a profound work of historical non-fiction that is also accessible and entertaining. This history of everyday life is rooted in details that are easy to overlook and from which great ideas develop. An inspiring example of innovative historiography.”

The members of the jury for the German Non-Fiction Prize 2023 are: Julika Griem (Institute for Advanced Study in the Humanities [KWI] Essen), Stefan Koldehoff (Deutschlandfunk), Michael Lemling (“Buchhandlung Lehmkuhl” bookshop), Markus Rex (Alfred Wegener Institute), Jeanne Rubner (Technical University of Munich), Adam Soboczynski (Die ZEIT) and Mirjam Zadoff (Munich Documentation Centre for the History of National Socialism).

The following books were also nominated for the award: Omri Boehm, Radikaler Universalismus. Jenseits von Identität (Propyläen); Teresa Bücker, Alle_Zeit. Eine Frage von Macht und Freiheit (Ullstein); Judith Kohlenberger, Das Fluchtparadox. Über unseren widersprüchlichen Umgang mit Vertreibung und Vertriebenen (Kremayr & Scheriau); Meron Mendel, Über Israel reden. Eine deutsche Debatte (Kiepenheuer & Witsch); Hanno Sauer, Moral. Die Erfindung von Gut und Böse (Piper); Martin Schulze Wessel, Der Fluch des Imperiums. Die Ukraine, Polen und der Irrweg in der russischen Geschichte (C.H.Beck) and Elisabeth Wellershaus, Wo die Fremde beginnt. Über Identität in der fragilen Gegenwart (C.H.Beck).

The Stiftung Buchkultur und Leseförderung des Börsenvereins des Deutschen Buchhandels (Foundation for Book Culture and the Promotion of Reading of the German Publishers and Booksellers Association) is awarding the German Non-Fiction Prize 2023 in recognition of the non-fiction book of the year, an original German-language edition of an outstanding work of non-fiction that inspires social debate.

The Deutsche Bank Stiftung (Deutsche Bank Foundation) is the main supporter of the prize, which is also backed by the city of Hamburg and the foundation ZEIT-Stiftung Ebelin und Gerd Bucerius. Minister of State for Culture Claudia Roth is patron of the prize.

A press photo of the winner will be available from approx. 8 p.m. at www.boersenverein.de/pressefotos.

Frankfurt am Main/Hamburg, 1 June 2023

Contact for the media:

 

Börsenverein des Deutschen Buchhandels e.V.

Thomas Koch, Head of Press and Public Relations

Tel. +49 (0) 69 1306-293, e-mail: t.koch@boev.de

Rebecca Ufert, PR Manager

Tel. +49 (0) 69 1306-330, e-mail: ufert@boev.de  

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Companies of Schwarz Group and Google to Sign Partnership to Jointly Deliver Sovereign, Secure Workplace Productivity Solutions for Germany and Europe14.11.2024 16:09:46 CET | Press Release

Schwarz Digits’ Cloud STACKIT will provide local data storage for Google Workspace and offer client-side encryption, delivering a sovereign and secure workplace productivity solution with XM Cyber as enhanced security layer. The partnership will integrate XM Cyber’s Continuous Exposure Management with Google Cloud’s Security portfolio to develop new joint security offerings targeted at public and private sector organizations. The companies of Schwarz Group with 575,000 employees will transition to Google Workspace to maximize security, efficiency, and control of its data sovereignty.

GEMA files model action to clarify AI providers‘ remuneration obligations in Europe13.11.2024 11:11:13 CET | Press Release

GEMA is the first collecting society worldwide to file a lawsuit against a provider of generative artificial intelligence (AI) systems for the unlicensed use of protected musical works. Specifically, it concerns the US company OpenAI, the autogenerative chatbot systems operator. GEMA accuses OpenAI of reproducing protected song lyrics by German authors without having acquired licenses or paid the authors in question. The aim is to prove that OpenAI systematically uses GEMA's repertoire to train its systems.

HEIDELBERG anticipates a very strong second half to financial year 2024/202513.11.2024 08:06:09 CET | Press Release

Incoming orders after six months above previous year’s level thanks to strong drupa orders High order backlog provides sound basis for projected sales volume in second half of the year, capacities being fully utilized Strong seasonality in financial year, with sales and EBITDA in the first half of the year within expectations Packaging solutions segment remains growth driver Annual forecast confirmed

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain7.11.2024 11:04:10 CET | Press Release

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye